Canada - English
Canada - Français
New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25.
For a refined risk estimateof local recurrence
The Oncotype DX GPS assay is fully covered by Medicare for localized prostate cancer patients.
Nuclear-specific vs. nuclear-agnostic AR-V7 testing
Help Stage II colon cancer patients understand the power of genomics
Your Oncotype DX score can help you decide.
Oncotype DX has helped thousands of women find out.
When Dan's Colon Recurrence Score came back low, he decided against chemotherapy.
Speaker Dr. Christy Russell, Senior Director of Medical Affairs at Exact Sciences, reviews data that were presented at SABCS 2020: RxPONDER, ADAPT and RSClin Education Tool
Order tests securely, access results quickly, sign documents, assign delegates, receive updates and more benefits available in one place.
Have questions? We're here to help.